echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%

    Children's drug concept stocks are booming, and many R&D and production companies report net profits increase by more than 30%

    • Last Update: 2021-10-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    According to news on October 9th, as of press time, Qianyuan Pharmaceuticals rose 3.
    63%, Kangzhi Pharmaceuticals rose 3.
    31%, Sunflower Pharmaceuticals rose 1.
    88%, Calabash Baby rose 1.
    69%, and Puli Pharmaceuticals rose 1.
    45%.
    In addition, Walter Dyne Also followed up
    .
    For a long time, children's medicines in our country have been faced with the problems of fewer children-specific varieties, fewer suitable dosage forms, and irregular use of medicines
    .
    Since the beginning of this year, with the release of a series of policies such as encouraging children's drug R&D and production, accelerating the approval of children's drug application, and the three-child policy, children's drug concept stocks have been on the move, and related children's drug R&D companies have also attracted the attention of the industry
    .
    It is understood that there are only more than 10 pharmaceutical companies specializing in children’s drugs in China.
    Among the listed companies that are engaged in the R&D and production of children’s drugs are Sunflower Pharmaceutical, Gourd Baby, Kangzhi Pharmaceutical, Yabao Pharmaceutical, Jianmin Group, Poinsettia, Qianyuan Pharmaceutical, Puli Pharmaceuticals, Huat Dyne and other enterprises
    .
    As of now, the interim reports of these pharmaceutical companies have all disclosed that they have performed well overall, with the interim net profits of many companies increasing by more than 30%
    .
    Sunflower Pharmaceuticals: Net profit increased by nearly 30% year-on-year.
    Sunflower Pharmaceuticals disclosed its interim report on August 26, 2021.
    The company achieved total operating income of 2.
    1 billion in the first half of 2021, a year-on-year increase of 31.
    4%; net profit attributable to parent company was 310 million, a year-on-year increase 29.
    6%; earnings per share is 0.
    53 yuan
    .
    Huluwa: Net profit increased by 22.
    11% year-on-year.
    Huluwa disclosed its interim report on August 27, 2021.
    The company's main operating income in the first half of the year was 631 million yuan, a year-on-year increase of 9.
    67%; net profit attributable to the parent was 51.
    915 million yuan, a year-on-year increase of 22.
    11%; The share return is 0.
    13 yuan
    .
    Kangzhi Pharmaceutical: Failed to maintain profitability On August 27, Kangzhi Pharmaceutical released the 2021 semi-annual report
    .
    The report shows that in the first half of 2021, Kangzhi Pharmaceutical's operating income was 424 million yuan, a year-on-year increase of 2.
    97%; net profit attributable to the parent was -57.
    637 million, compared with 7.
    45 million in the same period last year, failing to maintain profitability
    .
    Yabao Pharmaceuticals: Net profit increased by 62.
    7% Yabao Pharmaceuticals disclosed its interim report on August 21, 2021.
    The company achieved total operating income of 1.
    46 billion in the first half of 2021, a year-on-year increase of 27.
    2%; net profit attributable to the parent was 99.
    325 million, year-on-year An increase of 62.
    7%; earnings per share was 0.
    13 yuan
    .
    Jianmin Group: doubled net profit Jianmin Group’s 2021 interim report released in July showed that the company’s main operating income in the first half of the year was 1.
    793 billion yuan, a year-on-year increase of 74.
    5%; net profit attributable to the parent was 167 million yuan, a year-on-year increase of 192.
    24%; A profit of 159 million yuan, a year-on-year increase of 203.
    4%.
    Poinsettia: net profit increased by 46.
    61%.
    Poinsettia released a semi-annual performance report on the evening of July 29, stating that the operating income for the first half of 2021 was about 953 million yuan; the net profit attributable to shareholders of listed companies was about 1.
    18 Billion yuan, an increase of 46.
    61% year-on-year; basic earnings per share were 0.
    41 yuan
    .
    Qianyuan Pharmaceutical: Loss narrowed.
    Qianyuan Pharmaceutical disclosed its interim report on August 28, 2021.
    The company achieved total operating income of 460 million in the first half of 2021, a year-on-year increase of 16%; net profit attributable to the parent was -4.
    119 million, the same period last year It was 75.
    23 million yuan, and the loss narrowed
    .
    Basic earnings per share is -0.
    02 yuan
    .
    Puli Pharmaceuticals: Net profit increased by 42.
    06%.
    On August 10, Puli Pharmaceuticals released its 2021 semi-annual report, showing that in the first half of the year, it achieved revenue of 623 million yuan, a year-on-year increase of 55.
    11%; realized a net profit of 225 million yuan, a year-on-year increase of 42.
    06%; The deduction of non-net profit was 219 million yuan, a year-on-year increase of 39.
    27%
    .
    Walter Dyne: Net profit increased by 69.
    8%.
    Walter Dyne disclosed its semi-annual report on the evening of July 29.
    In the first half of 2021, the company achieved operating income of 1.
    011 billion yuan, a year-on-year increase of 21.
    45%; net profit attributable to shareholders of listed companies 229 million yuan, an increase of 69.
    8% year-on-year; basic earnings per share were 0.
    98 yuan
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.